Recursion Merges with Exscientia to Enhance Drug Discovery

Recursion has completed its merger with Exscientia, making Exscientia a wholly owned subsidiary and creating a robust AI-driven drug discovery platform. The combined entity boasts over 10 clinical and preclinical programs, 10 advanced discovery programs, and additional partnered initiatives, with the potential for over $20 billion in milestone payments. Chris Gibson, CEO of Recursion, expressed confidence in their enhanced capabilities to redefine drug discovery timelines and costs. David Hallett, formerly of Exscientia, now serves as CSO at Recursion, emphasizing their use of proprietary data for innovative drug candidate optimization. The merger is seen as a significant step in the industrialization of drug development, with headquarters remaining in Salt Lake City and additional offices in key cities across North America and Europe. Recursion aims to lead the AI-enabled drug discovery space with its technology-enhanced portfolio.